Chimeric Antigen Receptor Modified T Cells Infusion
Lung Neoplasm Malignant
The First Affiliated Hospital of Guangdong Pharmaceutical UniversityCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Lung Neoplasm Malignant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Patritumab Deruxtecan Merck Sharp & Dohme LLC | Phase 1/2 | CCC |
mk-1084 Merck Sharp & Dohme LLC | Phase 1/2 | CCC |
pd-1 knockout engineered t cells The First Affiliated Hospital of Guangdong Pharmaceutical University | Phase 1/2 | CCC |
Anti-Muc1 Car-T Cells The First Affiliated Hospital of Guangdong Pharmaceutical University | Phase 1/2 | CCC |
pd-1 knockout The First Affiliated Hospital of Guangdong Pharmaceutical University | Phase 1/2 | CCC |
SAR443216 Sanofi | Phase 1 | CC |
Pebezertinib Blueprint Medicines Corporation | Phase 1 | CC |
Same molecule, other indications
Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →